EN DE
Watch MEDIFAST INC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

MEDIFAST INC (MED) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of MEDIFAST INC stock $11.35, price $13.37, that is 15.1% below the price, quality 49 out of 100. Rating: overvalued. Calculated from audited financials with 9 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Cyclical US

MI MEDIFAST INC logo Some data Nov 8, 2026

MEDIFAST INC

MED · US
Expensive, weak quality

Our calculation puts a fair price 15% below what the stock costs today.

Low debt
Quality 49/100
Insiders bought $1.5M (6M) · sold $226,300
Some data
Revenue last quarter 19% below a year ago.
Fair value $11.35 · Overvalued
Weak Growth (revenue 5y −16.2 %/yr in USD)
Loss-making · -13.6% net margin (TTM)
Negative free cash flow over the last twelve months
Trails peers (4/13)
Narrow moat 8/100 · thin data
Watch MEDIFAST INC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$218.01 $9.45 Fair Value $11.35 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $9.45 – $218.01 · fair‑value band $10.75 – $12.26 · the $13.37 price screens above the $11.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow MEDIFAST in your weekly email

Every Wednesday you see whether MEDIFAST is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address weight loss in the United States.

Show moreShow less

The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, essential amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements.

It also provides lifestyle plans consisting of 5 & 1 Plan and 5 & 1 ACTIVE Plan, which provides a targeted reset of the body's metabolism by activating strong and targeted fat burn; Optimal Weight 4 & 2 & 1 Plan and Optimal Weight 4 & 2 ACTIVE Plan, which is designed for clients who want to continue eating all food groups or want a flexible meal plan to achieve a healthy weight; OPTAVIA Optimization Plan, a personalized approach to help clients' long-term weight management; and OPTAVIA GLP-1 Nutrition Support Plan, a nutritional companion to GLP-1 medication that allows clients to focus on weight loss without the stress of figuring out what to eat.

In addition, the company offers metabolic synchronization, a science that reverses metabolic dysfunction through a targeted reset of the body's metabolism. It markets its products through point-of-sale transactions executed over an e-commerce platform.

The company serves health and wellness consumers. The company was formerly known as Healthrite, Inc. and changed its name to Medifast, Inc. in May 2001. Medifast, Inc. was incorporated in 1980 and is headquartered in Baltimore, Maryland.

Stock analysis

MEDIFAST INC (MED) currently trades at $13.37, while our model-based Fair Value estimate is $11.35, 15% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $14.48 per share, and 2 of the 9 models we run sit above the $13.37 price.

Bear case: the Multiples group reads lowest at $7.23, and 7 of the 9 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $10.75 (bear) to $12.26 (bull), the price of $13.37 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Consumer Cyclical sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

MEDIFAST INC reported revenue of $386M in FY2025 versus $1.5B in FY2021, a compound −29.1%/yr. Reported net income was −$18.7M in FY2025.

Key figures

Market cap $149M Micro · P/S ratio 0.47 · EPS (TTM) $−2.33 · Dividend yield 0.1% · Net margin −4.8% · Return on equity −20.7% · Return on assets (EBIT) 29.8% (5-year average) · Operating margin −26.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 41% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Consumer Cyclical peers we cover trades at 6% fair-value upside, at −15%, MED screens richer than that median.

Fair Value models

Bear $10.75 Fair Value $11.35 Bull $12.26
Price $13.37 · Downside -15.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $12.33 $14.82 $18.39 82
Growth DCF $12.27 $14.48 $17.44 80
5Y EBITDA Exit $9.72 $10.02 $10.28 77
All 9 models by family
DCF Models
FCF DCF $12.33 $14.82 $18.39 82
5Y Revenue Exit $10.30 $11.19 $12.26 74
5Y EBITDA Exit $9.72 $10.02 $10.28 77
10Y Revenue Exit $11.06 $12.09 $13.45 68
10Y EBITDA Exit $10.75 $11.35 $12.02 70
Multiples
EV/EBITDA $6.51 $6.52 $6.53 67
EV/Revenue $7.50 $7.94 $8.37 54
Asset-Based
NCAV (Graham) $8.47 $12.84 $16.05 54
Growth DCF
Growth DCF $12.27 $14.48 $17.44 80

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 40
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 12
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 86
Does it invest with discipline instead of growing at any price?
Low Volatility 54
How calm the share price moves, does not count
Price momentum 49
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 74
Distance to the 52-week high, does not count
New shares 71
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $1.5M, most recently on Nov 4, 2026. Over the same period, one person sold shares worth $226,300. Buying cluster

  • BuyParsa KiaiDirector5× since Aug 19, 2026: 126,184 shares, avg. $11.89$1.5MNov 4, 2026
  • SaleDaniel R ChardDirector19,089 shares at $11.86$226,300Sep 29, 202610b5-1 plan
  • BuyScott SchlackmanDirector5,000 shares at $12.59$62,950May 11, 2026
  • BuyDaniel R ChardChairman & CEO, Director17,678 shares at $10.11$178,725Mar 20, 2026

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 9, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−36.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.2%
Start year 2020 (pandemic). Over 10 years: +3.5% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.4% (2020) → −3.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.

MED screens overvalued: fair value 15% below the price. Compare with Rollins, Inc →

Compare MEDIFAST INC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Personal Services · 40 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −15.1% · Below median
Profitability
Return on assets −7.3% · Bottom 25%
Net margin (12 months) −13.6% · Bottom 25%
Operating margin (12 months) −26.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −19.4% · Bottom 25%
Dividend yield (12 months) 0.1% · Bottom 25%

Valuation Multiplesvs Personal Services median · lower = cheaper

P/B 0.75× · Cheaper than median
P/S (12 months) 0.50× · Cheapest 25%
Price / free cash flow (fiscal year) 119.2× · Priciest 25%
PEG 0.97× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)13 · sector 43
FUTURE (revenue growth)0 · sector 24
PAST (return on equity)0 · sector 36
HEALTH (low debt)100 · sector 91
DIVIDEND (yield)3 · sector 66

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Personal Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
H&R Block, Inc HRB $50.98 $92.29 +81% vs MED
Musti Group MUSTI €14.65 €24.86 +70% vs MED
CEWE Stiftung & Co CWC €115.80 €156.87 +35% vs MED
Bright Horizons Family Solutions Inc BFAM $51.97 $69.81 +34% vs MED
Propel Funeral Partners Limited PFP A$2.72 A$2.88 +6% vs MED
Carriage Services, Inc CSV $28.63 $26.74 −7% vs MED
Frontdoor, Inc FTDR $100.73 $78.50 −22% vs MED
Service Corporation SCI $73.17 $53.61 −27% vs MED
Rollins, Inc ROL $38.74 $21.13 −45% vs MED
Lungyen Life Service Corporation 5530 44.95 TWD 15.88 TWD −65% vs MED

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MEDIFAST INC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MEDIFAST INC Fair Value". https://www.fairvalue-calculator.com/stock/MED

Frequently asked questions

Is MEDIFAST INC (MED) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $11.35 versus a price of $13.37, about 15% lower (overvalued).
What is the fair value of MED?
Our model-based fair value for MEDIFAST INC is $11.35 (as of Nov 8, 2026), built from audited fundamentals. The current price: $13.37.
What is the quality score of MED?
MEDIFAST INC has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MEDIFAST INC (MED)?
Our model-based price target is the fair value of $11.35 (as of Nov 8, 2026) from 9 valuation models. Cautious scenario $10.75, optimistic scenario $12.26. It is a calculation from audited fundamentals, not an analyst target.
What is the MEDIFAST INC stock forecast for 2026?
Our models put fair value at $11.35, about 15% lower versus a price of $13.37 (overvalued). Cautious scenario $10.75, optimistic scenario $12.26. The calculation is refreshed regularly with new filings.
What is the revenue of MEDIFAST INC (MED)?
MEDIFAST INC reported trailing-twelve-month revenue of about $300M (latest available figure, as of Nov 8, 2026).
Does MEDIFAST INC pay a dividend?
MEDIFAST INC currently shows a dividend yield of 0.14% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of MEDIFAST INC (MED)?
MEDIFAST INC has a dividend yield of 0.1%.
What growth is priced into MEDIFAST INC (MED)?
For today's price to be fair in a discounted-cash-flow model, MEDIFAST INC would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -16.2 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of MED use?
Our models discount MEDIFAST INC at 11.8 %: a base by market capitalisation (micro), damped by beta 0.70, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MEDIFAST INC that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has MEDIFAST INC (MED) delivered so far?
Over the past 5 years revenue at MEDIFAST INC grew -16.2 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MEDIFAST INC (MED) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into MEDIFAST INC (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MEDIFAST INC (MED)?
The free-cash-flow yield on the price is 0.84 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow MEDIFAST INC produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MEDIFAST INC (MED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MEDIFAST INC it is $11.35 per share (as of Nov 8, 2026), against a price of $13.37. It is the blended result of 9 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is MEDIFAST INC stock overvalued or undervalued in 2026?
As of Nov 8, 2026, MED trades above its calculated fair value: price $13.37, fair value $11.35, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MED?
No. The price is what the market pays today ($13.37); the fair value is what the company's own numbers justify ($11.35). For MEDIFAST INC the two are $2.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is MEDIFAST INC worth?
The market values MEDIFAST INC at about $149M (market capitalisation, as of Nov 8, 2026). Per share that is $13.37; our models calculate a fair value of $11.35 per share.
What do the bullish and bearish scenarios say about MED?
Our models span a range for MEDIFAST INC: cautious scenario $10.75, base $11.35, optimistic $12.26 per share (as of Nov 8, 2026, price $13.37). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MED?
The PEG ratio of MEDIFAST INC is 0.97 (P/E divided by earnings growth, as of Nov 8, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of MEDIFAST INC (MED)?
Balance-sheet figures for MEDIFAST INC (as of Nov 8, 2026): return on equity −20.7%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is MED from its 52-week high?
MEDIFAST INC trades at $13.37, at its 52-week high of $13.37 and 41% above the low of $9.45 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of $11.35 is for.
Which stocks are comparable to MEDIFAST INC?
From the same area (Consumer Cyclical) we also value Rollins, Inc, Service Corporation, Frontdoor, Inc, H&R Block, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MEDIFAST INC stock attractive at the current price?
The data as of Nov 8, 2026: price $13.37, calculated fair value $11.35 (−15%), Quality Score 49/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MED calculated?
We run MEDIFAST INC through 9 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $11.35 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. MEDIFAST INC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MEDIFAST INC (MED)?
The closing price on Nov 9, 2026 was $13.37. Our model-based fair value is $11.35, about 15% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MEDIFAST INC right now?
The price sits above even our optimistic bull case ($12.26). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band ($10.75 to $12.26), unusually little disagreement for a valuation.
Where does the earnings growth of MEDIFAST INC (MED) come from?
Earnings per share at MEDIFAST INC grew +15.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +15.4 %, EBIT margin −3.3 %, tax rate +2.3 %, residual (interest, one-offs) +1.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of MEDIFAST INC

How large is the market capitalisation of MEDIFAST INC (MED)?
The market capitalisation of MEDIFAST INC is $149M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MEDIFAST INC (MED)?
The price-to-sales ratio of MEDIFAST INC is 0.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MEDIFAST INC (MED)?
Earnings per share at MEDIFAST INC are $−2.33. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of MEDIFAST INC (MED)?
The dividend yield of MEDIFAST INC is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of MEDIFAST INC (MED)?
The net margin of MEDIFAST INC is −4.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MEDIFAST INC (MED)?
The return on equity (ROE) of MEDIFAST INC is −20.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MEDIFAST INC (MED)?
On an EBIT basis the return on assets of MEDIFAST INC is 29.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MEDIFAST INC (MED)?
The operating margin of MEDIFAST INC is −26.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MEDIFAST INC (MED)?
Revenue at MEDIFAST INC is growing −19.4% versus a year earlier (3y avg −37.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MEDIFAST INC (MED)?
Earnings per share at MEDIFAST INC are growing −87.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does MEDIFAST INC (MED) hold?
MEDIFAST INC holds more cash than debt, $72.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch MEDIFAST INC in the live analysis

One click puts MEDIFAST INC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.